Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2021-02-04 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于持股5%以上股东减持及被动稀释股份比例达到1%的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding changes in shareholding by a shareholder holding more than 5% of the company's shares. It details the reduction in shareholding percentage due to share sales and passive dilution from a specific stock issuance. The document includes specific dates, share quantities, and compliance with disclosure regulations. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It fits the definition of a Major Shareholding Notification, which involves notifying changes in significant share ownership levels crossing thresholds.
2021-02-04 Chinese
董事、监事和高级管理人员持股情况变动报告
Director's Dealing Classification · 95% confidence The document is titled as a report on changes in shareholdings of directors, supervisors, and senior management personnel of Shenzhen BGI Genomics Co., Ltd. It details the number of shares held before and after a specific stock issuance event, including the dilution effect on their holdings. The content focuses on insider shareholding changes rather than financial results, board changes, or voting outcomes. It is not an announcement of a report publication, nor a certification or legal proceeding. The document fits the definition of 'Director's Dealing' as it reports personal share transactions by company directors and executives (insider trades). The document length is short (1562 characters), consistent with such reports. Therefore, the correct classification is DIRS with high confidence.
2021-02-04 Chinese
关于控股子公司新冠抗原检测产品获得CE准入资质的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a subsidiary's COVID-19 antigen detection product obtaining CE certification. It includes product details, market context, and impact on the company. There are no financial statements, earnings data, or detailed financial analysis. The document is relatively short (2092 characters) and serves as a regulatory announcement about product certification and market impact rather than a financial report or management discussion. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about product certification and market impact without financial data or report content.
2021-02-04 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司向特定对象发行股票之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" which translates to "Listing Sponsorship Letter" or "Sponsorship Document for Stock Issuance to Specific Objects." It is issued by 中信证券股份有限公司 (CITIC Securities) as the sponsor for 深圳华大基因股份有限公司 (BGI Genomics Co., Ltd.) for a specific stock issuance. The content includes detailed information about the issuer, business overview, core technologies, financial data, risk factors, and compliance related to the issuance. It is a comprehensive document related to a capital raising event through a specific stock issuance to targeted investors. This type of document is not an annual report, earnings release, or management report, but rather a detailed capital/financing update and sponsorship document related to a stock issuance. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed financial and business information support this classification rather than a brief announcement or regulatory filing.
2021-02-04 Chinese
向特定对象发行股票上市公告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市公告书" which translates to "Listing Announcement" or "Announcement of Stock Issuance and Listing". It details the issuance of new shares to specific investors, including the number of shares issued, pricing, total funds raised, lock-up periods, and the listing date of the new shares on the Shenzhen Stock Exchange. It also includes information about the shareholders before and after the issuance, the approval process by regulatory bodies such as the China Securities Regulatory Commission (CSRC), and compliance opinions from the sponsor and legal counsel. The document is comprehensive and contains detailed financial and procedural information about the capital raising event. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not an announcement of a report publication, nor a full annual or interim report, nor a regulatory filing or proxy statement. Therefore, the correct classification is CAP with high confidence.
2021-02-04 Chinese
关于股东减持股份比例超过1%暨减持计划实施完成的公告
Major Shareholding Notification Classification · 100% confidence The document is an official announcement from Shenzhen BGI Genomics Co., Ltd. regarding the completion of a shareholder share reduction plan where shareholders holding more than 5% of shares have reduced their holdings by more than 1%. It details the shareholding changes, reduction methods, dates, and compliance with relevant securities laws and regulations. The document does not contain financial statements or performance data but focuses on shareholding changes and disclosures related to shareholder transactions. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document length is over 7,000 characters and contains detailed data on shareholding changes, consistent with MRQ filings rather than a simple announcement or other categories.
2021-02-04 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.